Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Parentheticals) (unaudited)

v3.23.1
Condensed Consolidated Balance Sheets (Parentheticals) (unaudited) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Payroll liabilities ($0.9 million and $0.6 million attributable to VIE) $ 3,571,008 $ 2,030,510
Deferred revenue from company clinics attributable to VIE $ 2,978,937 $ 2,955,851
Series A preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Series A preferred stock, shares authorized (in shares) 50,000 50,000
Series A preferred stock, shares issued (in shares) 0 0
Series A preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 20,000,000 20,000,000
Common stock, shares issued (in shares) 14,671,360 14,560,353
Common stock, shares outstanding (in shares) 14,639,325 14,528,487
Balance, beginning treasury stock (in shares) 32,035 31,866
Variable Interest Entity, Primary Beneficiary    
Payroll liabilities ($0.9 million and $0.6 million attributable to VIE) $ 900,000 $ 600,000
Deferred revenue from company clinics attributable to VIE $ 4,900,000 $ 4,700,000